Corporate Governance

Corporate Governance

Press Releases View all

September 3, 2019

BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

September 3, 2019

BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

August 6, 2019

BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Upcoming Events View all